|
|
Blood, 15 August 2006, Vol. 108, No. 4, pp. 1328-1333.
Prepublished online as a Blood First Edition Paper on April 13, 2006; DOI 10.1182/blood-2005-12-010132.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)
Nikolas von Bubnoff,
Paul W. Manley,
Jurgen Mestan,
Jana Sanger,
Christian Peschel, and
Justus Duyster
From the Department of Internal Medicine III, Technical University of Munich, Germany; and Novartis Institutes of Biomedical Research, Basel, Switzerland.
In advanced-phase chronic myeloid leukemia (CML), resistance to imatinib mesylate is associated with point mutations in the BCR-ABL kinase domain. A new generation of potent ABL kinase inhibitors is undergoing clinical evaluation. It is important to generate specific resistance profiles for each of these compounds, which could translate into combinatorial and sequential treatment strategies. Having characterized nilotinib (AMN107) against a large panel of imatinib mesylate–resistant Bcr-Abl mutants, we investigated which mutants might arise under nilotinib therapy using a cell-based resistance screen. In contrast to imatinib mesylate, resistance to nilotinib was associated with a limited spectrum of Bcr-Abl kinase mutations. Among these were mutations affecting the P-loop and T315I. Rarely emerging resistant colonies at a concentration of 400 nM nilotinib exclusively expressed the T315I mutation. With the exception of T315I, all of the mutations that were identified were effectively suppressed when the nilotinib concentration was increased to 2000 nM, which falls within the peak-trough range in plasma levels (3.6-1.7 µM) measured in patients treated with 400 mg twice daily. Our findings suggest that nilotinib might be superior to imatinib mesylate in terms of the development of resistance. However, our study indicates that clinical resistance to nilotinib may be associated with the predominant emergence of T315I.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Gontarewicz, S. Balabanov, G. Keller, R. Colombo, A. Graziano, E. Pesenti, D. Benten, C. Bokemeyer, W. Fiedler, J. Moll, et al.
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I
Blood,
April 15, 2008;
111(8):
4355 - 4364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Carayol, E. Katsoulidis, A. Sassano, J. K. Altman, B. J. Druker, and L. C. Platanias
Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway
J. Biol. Chem.,
March 28, 2008;
283(13):
8601 - 8610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Baccarani, F. Pane, and G. Saglio
Monitoring treatment of chronic myeloid leukemia
Haematologica,
February 1, 2008;
93(2):
161 - 169.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cortes, E. Jabbour, H. Kantarjian, C. C. Yin, J. Shan, S. O'Brien, G. Garcia-Manero, F. Giles, M. Breeden, N. Reeves, et al.
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
Blood,
December 1, 2007;
110(12):
4005 - 4011.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. O'Hare, C. A. Eide, and M. W. N. Deininger
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Blood,
October 1, 2007;
110(7):
2242 - 2249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Scheich, J. Duyster, C. Peschel, and H. Bernhard
The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens
Blood,
October 1, 2007;
110(7):
2556 - 2560.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Modugno, E. Casale, C. Soncini, P. Rosettani, R. Colombo, R. Lupi, L. Rusconi, D. Fancelli, P. Carpinelli, A. D. Cameron, et al.
Crystal Structure of the T315I Abl Mutant in Complex with the Aurora Kinases Inhibitor PHA-739358
Cancer Res.,
September 1, 2007;
67(17):
7987 - 7990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rahmani, T. K. Nguyen, P. Dent, and S. Grant
The Multikinase Inhibitor Sorafenib Induces Apoptosis in Highly Imatinib Mesylate-Resistant Bcr/Abl+ Human Leukemia Cells in Association with Signal Transducer and Activator of Transcription 5 Inhibition and Myeloid Cell Leukemia-1 Down-Regulation
Mol. Pharmacol.,
September 1, 2007;
72(3):
788 - 795.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Rink, A. Slupianek, T. Stoklosa, M. Nieborowska-Skorska, K. Urbanska, I. Seferynska, K. Reiss, and T. Skorski
Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells
Blood,
July 15, 2007;
110(2):
651 - 660.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Weisberg, L. Catley, R. D. Wright, D. Moreno, L. Banerji, A. Ray, P. W. Manley, J. Mestan, D. Fabbro, J. Jiang, et al.
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias
Blood,
March 1, 2007;
109(5):
2112 - 2120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Branford
Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice
Hematology,
January 1, 2007;
2007(1):
376 - 383.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
